Viewing Study NCT05253651


Ignite Creation Date: 2025-12-24 @ 11:39 PM
Ignite Modification Date: 2025-12-25 @ 9:29 PM
Study NCT ID: NCT05253651
Status: RECRUITING
Last Update Posted: 2025-12-17
First Post: 2022-02-14
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module